Dysport
Botulinum Toxin Type A for Muscle Spasticity, Dystonia, and Hyperhidrosis
Quick Facts About Dysport
Key Takeaways About Dysport
- Specialist-only administration: Dysport must be given only by physicians with specific training and experience in using botulinum toxin products
- Non-interchangeable units: The potency units for Dysport are specific and cannot be compared to or converted into units of any other botulinum toxin product (e.g. Botox, Xeomin)
- Multiple indications: Treats upper and lower limb spasticity in adults, paediatric spasticity in children aged 2+, cervical dystonia, blepharospasm, hyperhidrosis, and neurogenic urinary incontinence
- Temporary effect: Effects typically last 12–16 weeks; repeat treatments are scheduled as the benefit wears off, with the dose and frequency determined by your doctor
- Risk of distant spread: In rare cases, toxin effect may spread beyond the injection site, causing potentially serious swallowing or breathing difficulties – seek immediate medical attention if this occurs
What Is Dysport and What Is It Used For?
Dysport is a neuromuscular blocking agent that contains botulinum toxin type A. It works by blocking the transmission of nerve impulses to muscles or sweat glands, thereby reducing muscle spasm or excessive sweating at the injection site. It is used to treat a range of conditions involving involuntary muscle contraction or overactive glands.
Dysport (abobotulinumtoxinA) belongs to a class of biological medicines derived from the bacterium Clostridium botulinum. The active substance is a purified form of the botulinum toxin type A haemagglutinin complex. When injected into a specific muscle, Dysport blocks the release of acetylcholine at the neuromuscular junction – the chemical messenger that causes muscles to contract. This produces a controlled, localised weakening of the targeted muscle, reducing spasm and involuntary contraction without affecting consciousness or sensation.
The mechanism is highly selective: Dysport acts only at the site of injection and does not cross the blood-brain barrier. The onset of effect typically occurs within 2 to 3 days after injection, with the peak therapeutic effect developing over 2 to 4 weeks. As nerve terminals gradually regenerate through a process known as axonal sprouting, the effect wears off over approximately 12 to 16 weeks, at which point treatment can be repeated.
Dysport is approved for the treatment of the following conditions:
- Upper limb spasticity in adults – involuntary muscle spasms in the arm and shoulder following stroke, brain injury, or other neurological conditions
- Lower limb spasticity in adults – equinus foot posture (toe-walking) caused by spastic muscles in the leg
- Paediatric lower limb spasticity – equinus foot deformity in ambulatory children aged 2 years and older due to cerebral palsy
- Paediatric upper limb spasticity – arm spasticity in children aged 2 years and older with cerebral palsy
- Cervical dystonia (spasmodic torticollis) – involuntary muscle contractions in the neck and shoulder region causing abnormal head posture and pain
- Blepharospasm – involuntary, sustained contraction of the eyelid muscles
- Hemifacial spasm – involuntary muscle spasms on one side of the face
- Severe primary axillary hyperhidrosis – excessive underarm sweating that interferes with daily activities and does not respond to topical treatments
- Neurogenic detrusor overactivity – urinary incontinence in adults caused by bladder dysfunction associated with spinal cord injury or multiple sclerosis, in patients who perform clean intermittent catheterisation (CIC)
Dysport was first approved for medical use in the United Kingdom in 1990 and is now licensed in over 80 countries worldwide. The potency units used for Dysport are product-specific and are not interchangeable with those of any other botulinum toxin product, including Botox (onabotulinumtoxinA) or Xeomin (incobotulinumtoxinA). Your doctor will always specify the product and dose individually.
What Should You Know Before Receiving Dysport?
Before receiving Dysport, your doctor needs to know about any neuromuscular disorders, swallowing or breathing problems, bleeding disorders, and all medications you are taking. Dysport is contraindicated in patients with known hypersensitivity to botulinum toxin type A or any excipient, and in patients with urinary tract infection (for bladder injection).
Contraindications
You should not receive Dysport if any of the following apply:
- Allergy to botulinum toxin type A or any ingredient in Dysport (including human albumin and lactose) – symptoms may include skin rash, itching, or difficulty breathing
- Active urinary tract infection – if you are scheduled for bladder injection for urinary incontinence, treatment must be postponed until the infection has been treated
- Infection or inflammation at the proposed injection site – treatment should be delayed until the condition resolves
Warnings and Precautions
Talk to your doctor before receiving Dysport if you have or have had any of the following:
- Swallowing or breathing difficulties – even if unrelated to the reason for treatment, as Dysport may worsen these symptoms
- Neuromuscular disorders such as myasthenia gravis, Lambert-Eaton syndrome, or motor neurone disease – these conditions increase the risk of severe generalised weakness following injection
- Fixed muscle contractures – Dysport is effective for dynamic spasticity but cannot treat established structural shortening of muscles or tendons
- Bleeding disorders or treatment with anticoagulant medications – there is a risk of bruising or bleeding at the injection site
- Significant muscle atrophy at the proposed injection site – the response may be altered and the risk of weakness increased
Dysport contains a small amount of human albumin. Although the manufacturing process includes steps to minimise the risk, the possibility of transmission of viral infection cannot be entirely excluded when using products derived from human blood or plasma.
- Difficulty swallowing, speaking, or breathing after a Dysport injection
- Generalised muscle weakness or loss of strength beyond the injection site
- Signs of allergic reaction: rash, itching, swelling of the face, lips, tongue or throat, or wheezing
Pregnancy and Breastfeeding
The safety of Dysport during pregnancy has not been established. Use during pregnancy is not recommended unless your doctor considers the treatment to be essential. If you are pregnant, think you might be pregnant, or are planning to become pregnant, inform your doctor before receiving Dysport.
It is not known whether Dysport passes into breast milk. Use during breastfeeding is not recommended. Discuss the risks and benefits with your doctor if you are breastfeeding.
Driving and Operating Machinery
Dysport can cause muscle weakness, blurred vision, double vision, and reduced visual acuity. These effects may impair your ability to drive or operate machinery. Do not drive or use machines until you are confident that these effects have resolved. The risk of visual disturbance is particularly relevant when Dysport is injected around the eyes for blepharospasm or hemifacial spasm.
Autonomic Dysreflexia (Bladder Treatment)
When Dysport is injected into the bladder for treatment of neurogenic urinary incontinence, you may experience autonomic dysreflexia – a potentially serious condition characterised by sudden excessive sweating, throbbing headache, elevated blood pressure, or increased heart rate. This reaction is related to the cystoscopy procedure rather than the medication itself. Your doctor will monitor you for at least 30 minutes after the procedure.
How Does Dysport Interact with Other Drugs?
Medications that affect neuromuscular function can enhance the effect of Dysport and increase the risk of excessive muscle weakness. These include aminoglycoside antibiotics, spectinomycin, neuromuscular blocking agents, lincosamides, polymyxins, quinidine, and magnesium sulphate. Always inform your doctor about all medications you are taking.
Dysport acts at the neuromuscular junction by blocking acetylcholine release. Other drugs that interfere with neuromuscular transmission can potentiate this effect, leading to exaggerated or prolonged muscle weakness. The risk of interaction is highest when these medications are used concurrently or within a few weeks of Dysport injection. Your doctor will carefully consider these interactions when planning your treatment.
Major Interactions
| Drug / Drug Class | Category | Effect | Recommendation |
|---|---|---|---|
| Aminoglycosides (gentamicin, tobramycin, amikacin) | Antibiotic | Potentiate neuromuscular blockade; risk of severe generalised weakness | Avoid concurrent use if possible; monitor closely for weakness |
| Neuromuscular blocking agents (tubocurarine, pancuronium) | Anaesthetic agent | Additive neuromuscular blockade; prolonged paralysis | Use extreme caution; reduced doses of neuromuscular blockers may be needed |
| Other botulinum toxin products | Neurotoxin | Risk of excessive and prolonged neuromuscular blockade | Do not administer until the effects of a previous botulinum toxin injection have fully worn off |
| Spectinomycin | Antibiotic | Enhances neuromuscular blockade | Avoid concurrent use; use alternative antibiotic if possible |
Moderate Interactions
| Drug / Drug Class | Category | Effect | Recommendation |
|---|---|---|---|
| Lincosamides (clindamycin, lincomycin) | Antibiotic | May enhance neuromuscular blockade | Monitor for increased muscle weakness if concurrent use is necessary |
| Polymyxins (colistin, polymyxin B) | Antibiotic | Can potentiate neuromuscular blockade | Use with caution; monitor neuromuscular function |
| Quinidine | Antiarrhythmic | May enhance the effect of Dysport through neuromuscular blockade | Monitor for increased weakness; consider dose adjustment |
| Magnesium sulphate | Electrolyte supplement | May potentiate neuromuscular blockade | Use with caution; particularly relevant in hospital settings |
| Anticholinesterases (neostigmine, pyridostigmine) | Myasthenia gravis treatment | May reduce the effect of Dysport | Consider that efficacy of Dysport may be diminished |
| Anticoagulants (warfarin, heparin, DOACs) | Blood thinners | Increased risk of bruising and bleeding at injection site | Doctor may adjust anticoagulation therapy before and after injections |
If you are receiving Dysport for bladder injection, your doctor will prescribe prophylactic antibiotics to prevent urinary tract infection. If you are taking blood-thinning medications, your doctor will adjust your treatment plan before and after the Dysport injections. Always inform your doctor of all prescription and over-the-counter medications, vitamins, and herbal supplements you are currently using.
What Is the Correct Dosage of Dysport?
Dysport doses are determined individually by your doctor based on the condition being treated, the muscles involved, and your clinical response. The dose varies significantly between indications – from 40 units per eye for blepharospasm to 800 units for neurogenic bladder. Dysport must be reconstituted from powder before injection and is administered only by trained specialists.
The dosing of Dysport is complex and highly individualised. Unlike most medications where patients take a fixed number of tablets, Dysport doses are determined by the treating physician based on the specific condition, the size and number of muscles to be injected, prior treatment response, and patient body weight (particularly in children). The following sections provide an overview of typical dosing ranges for each approved indication.
Adult Upper Limb Spasticity
Arm and Shoulder Spasticity
Typical total dose: 500–1,000 units, divided among affected muscles
Maximum dose per treatment session: 1,500 units
The dose is distributed across multiple muscles in the arm and shoulder. Your doctor will determine the specific injection sites using anatomical landmarks or guidance techniques (such as electromyography or ultrasound). Treatments are typically repeated every 12–16 weeks.
Adult Lower Limb Spasticity
Equinus Foot Deformity
Typical total dose: 1,000–1,500 units, divided among affected muscles
The dose depends on the number and size of muscles contributing to the spasticity pattern. Injections are given into the calf muscles (gastrocnemius, soleus, tibialis posterior) and other affected muscles as determined by the treating physician.
Children (2 Years and Older – Cerebral Palsy)
Lower Limb Spasticity (Equinus Foot)
Initial dose: 10 units/kg body weight per leg (unilateral) or 15 units/kg divided between both legs (bilateral)
Subsequent doses: May be increased to up to 15 units/kg per leg (unilateral) or 30 units/kg total (bilateral)
Treatment is repeated at intervals of not less than 12 weeks. Doses are weight-based and must be carefully calculated by the treating physician.
Upper Limb Spasticity (Cerebral Palsy)
Recommended dose: 8–16 units/kg body weight, divided among affected muscles in the arm
When upper and lower limb spasticity are treated simultaneously, the total combined dose should not exceed recommended limits as determined by your doctor.
Cervical Dystonia (Adults)
Spasmodic Torticollis
Typical initial dose: 500 units, divided among 2–4 affected muscles
Dose range: 250–1,000 units depending on muscle size and severity
The dose is individually adjusted based on the pattern of muscle involvement. Treatment intervals are typically every 12–16 weeks. Dysport is reconstituted to a concentration of 500 units/ml for cervical dystonia.
Blepharospasm and Hemifacial Spasm (Adults)
Eyelid and Facial Spasm
Initial dose: 40 units per eye for blepharospasm (20 units medially and 20 units laterally into the junction of the preseptal and orbital parts of each upper and lower orbicularis oculi)
Maximum dose per eye: 60 units (subsequent doses may be increased by 10-unit increments)
Dysport is reconstituted to a concentration of 200 units/ml for this indication. When treating hemifacial spasm, injection into other facial muscles may also be required.
Severe Axillary Hyperhidrosis (Adults)
Excessive Underarm Sweating
Dose: 50 units per axilla (100 units total)
Dysport is reconstituted to 200 units/ml and injected intradermally into 10–15 sites evenly spaced across the sweat-producing area in each armpit. The effect typically lasts for several months. Repeat treatment is given when sweating returns.
Neurogenic Detrusor Overactivity (Adults)
Urinary Incontinence Due to Spinal Cord Injury or Multiple Sclerosis
Recommended dose: 600–800 units
Dysport is injected into the bladder wall (detrusor muscle) via cystoscopy. The reconstituted solution is divided into two syringes and injected at approximately 30 sites across the bladder wall. This procedure is performed under local or general anaesthesia, and patients are monitored for at least 30 minutes afterwards. Treatment is only offered to patients who are already performing clean intermittent catheterisation (CIC).
Overdose
Excessive doses of Dysport may cause weakness in muscles other than those injected. Very high doses can potentially cause muscle paralysis. These effects may not occur immediately and can develop over several days. If you experience difficulty breathing, swallowing, or speaking after treatment, seek emergency medical attention immediately. There is no specific antidote for botulinum toxin overdose; treatment is supportive and may require respiratory support in severe cases.
What Are the Side Effects of Dysport?
The most common side effects of Dysport depend on the treated area. General effects across all indications include localised muscle weakness, fatigue, flu-like symptoms, and injection site pain. Swallowing difficulty is a very common side effect when treating cervical dystonia. Eyelid drooping is very common when treating blepharospasm. Most side effects are temporary.
Like all medicines, Dysport can cause side effects, although not everybody gets them. Side effects are generally localised to the treated area and are a consequence of the pharmacological action of the toxin. Most side effects appear within the first few days to two weeks after injection and resolve as the effect of the toxin wears off. The nature and frequency of side effects vary considerably depending on the indication and muscles treated.
- Difficulty swallowing, speaking, or breathing
- Swelling of the face, lips, tongue, or throat (signs of allergic reaction)
- Itchy skin rash or hives (urticaria) spreading over the body
- Generalised muscle weakness affecting areas remote from the injection site
General Side Effects (All Indications)
Common
May affect up to 1 in 10 people
- Localised muscle weakness
- Fatigue and tiredness
- Flu-like symptoms
- Pain or tenderness at the injection site
Uncommon
May affect up to 1 in 100 people
- Itching (pruritus)
Rare
May affect up to 1 in 1,000 people
- Muscle wasting (atrophy)
- Skin rash
- Numbness (paraesthesia)
Side Effects by Treatment Area
Cervical Dystonia
Very Common
May affect more than 1 in 10 people
- Swallowing difficulties (dysphagia)
- Dry mouth
- Muscle weakness
Common
May affect up to 1 in 10 people
- Headache, dizziness
- Facial muscle weakness
- Blurred vision, reduced visual acuity
- Voice changes (dysphonia)
- Breathing difficulties
- Neck pain, musculoskeletal pain and stiffness
- Pain in arms and legs
Uncommon
May affect up to 1 in 100 people
- Double vision (diplopia)
- Drooping eyelid (ptosis)
- Nausea
- Muscle atrophy
- Jaw dysfunction
Rare
May affect up to 1 in 1,000 people
- Aspiration (inhalation of food or saliva into the lungs)
Blepharospasm and Hemifacial Spasm
Very Common
May affect more than 1 in 10 people
- Drooping eyelid (ptosis)
Common
May affect up to 1 in 10 people
- Facial muscle weakness
- Double vision (diplopia)
- Dry eyes
- Increased tear production
- Eyelid swelling
Uncommon
May affect up to 1 in 100 people
- Facial paralysis
Rare
May affect up to 1 in 1,000 people
- Eye muscle paralysis (ophthalmoplegia)
- Entropion (inward turning of the eyelid margin)
Upper and Lower Limb Spasticity (Adults)
Common
May affect up to 1 in 10 people
- Muscle weakness (localised and generalised)
- Musculoskeletal pain
- Pain, redness, swelling, or bruising at injection site
- Fatigue, tiredness, flu-like symptoms
- Swallowing difficulties (lower limb treatment)
- Falls (lower limb treatment)
- Pain in hands and fingers (upper limb treatment)
Uncommon
May affect up to 1 in 100 people
- Swallowing difficulties (upper limb treatment)
Paediatric Spasticity (Children, 2 Years and Older)
Common
May affect up to 1 in 10 people
- Muscle pain, localised and generalised muscle weakness
- Urinary incontinence
- Flu-like symptoms
- Pain, redness, or bruising at injection site
- Abnormal gait, falls, fatigue
- Skin rash (upper limb treatment)
Uncommon
May affect up to 1 in 100 people
- Swallowing difficulties
- Eczema or swelling at injection site
Severe Axillary Hyperhidrosis
Common
May affect up to 1 in 10 people
- Pain in shoulders, upper arm, and neck
- Muscle pain in shoulders and calves
- Breathing difficulties
- Compensatory sweating (increased sweating in other body areas)
Uncommon
May affect up to 1 in 100 people
- Dizziness, headache
- Numbness and tingling in arms and legs
- Nosebleed (epistaxis)
- Flushing, involuntary eyelid spasm
Rare
May affect up to 1 in 1,000 people
- Allergic reactions including skin rash
Neurogenic Urinary Incontinence
Common
May affect up to 1 in 10 people
- Blood in urine (haematuria)*
- Constipation
- Bacteria in urine (bacteriuria)*
- Erectile dysfunction
- Urinary tract infection*
- Headache, fever
Uncommon
May affect up to 1 in 100 people
- Numbness, muscle weakness
- Bladder pain*
- Autonomic dysreflexia*
- Urinary retention (inability to empty the bladder)
- Urethral or bladder bleeding
* These side effects may be related to the cystoscopy procedure rather than Dysport itself.
If you experience any side effects not listed here, or if any side effect becomes severe or persistent, contact your doctor or pharmacist. Reporting suspected adverse reactions contributes to ongoing safety monitoring of the medicine.
How Should You Store Dysport?
Unopened Dysport vials must be stored in a refrigerator at 2–8°C. Do not freeze. Unopened vials may be stored once at temperatures up to 25°C for a maximum of 72 hours, after which they must be returned to refrigerated storage. Once reconstituted, the solution should be used immediately or within 24 hours if refrigerated.
Store Dysport out of sight and reach of children. Do not use the medicine after the expiry date (marked "EXP" on the carton and vial label). The expiry date refers to the last day of the stated month.
Unopened vials: Store in a refrigerator at 2–8°C. Unopened Dysport vials may be stored on one occasion at temperatures up to 25°C for a maximum of 72 hours. After this period, the unopened vial must be returned to refrigerated storage (2–8°C) for the remainder of its shelf life. Do not freeze.
Reconstituted solution: It is recommended that the reconstituted solution be used immediately after preparation. If not used immediately, it may be stored in a refrigerator at 2–8°C for up to 24 hours. Do not use the solution if it appears cloudy or contains particulate matter.
Do not dispose of medicines via household waste or wastewater. Return unused or expired medication to your pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination. Any used vials, syringes, and materials with spill should be autoclaved or decontaminated with a 0.5% sodium hypochlorite solution before disposal.
What Does Dysport Contain?
Each vial of Dysport contains 300 units of Clostridium botulinum toxin type A haemagglutinin complex as the active ingredient, along with human albumin and lactose as excipients. Dysport is a white freeze-dried powder that must be reconstituted with sterile saline before use.
Active Ingredient
The active substance is Clostridium botulinum toxin type A haemagglutinin complex, 300 units per vial. The units specified for Dysport are product-specific and are not transferable to other botulinum toxin products. This means that 300 units of Dysport is not equivalent to 300 units of Botox (onabotulinumtoxinA) or any other botulinum toxin product. The differing potency assays and biological characteristics of each product require completely separate dosing guidelines.
Excipients (Inactive Ingredients)
The other ingredients are:
- Human albumin – a stabilising protein derived from human plasma. Dysport contains a small amount of human albumin to help maintain the stability and biological activity of the botulinum toxin.
- Lactose – a sugar used as a bulking agent and stabiliser in the freeze-dried powder. Patients with lactose intolerance should note that the amount of lactose in Dysport is very small and administered by injection (not orally), so it is not expected to cause symptoms.
Appearance and Packaging
Dysport is supplied as a white freeze-dried (lyophilised) powder in a clear, colourless Type I glass vial, sealed with a rubber stopper and aluminium cap. Each carton contains either 1 or 2 vials. Before use, the powder is reconstituted with preservative-free sodium chloride 9 mg/ml (0.9%) solution for injection using a sterile 23- or 25-gauge needle.
Manufacturer
Dysport is manufactured by Ipsen Manufacturing Ireland Limited, Blanchardstown Industrial Park, Dublin 15, Ireland. The marketing authorisation holder is Ipsen. Dysport is approved and marketed in more than 80 countries worldwide for a variety of neuromuscular conditions.
Frequently Asked Questions About Dysport
Dysport is used to treat several conditions involving involuntary muscle contraction or overactive glands. These include upper and lower limb spasticity in adults (e.g. after stroke), paediatric limb spasticity in children with cerebral palsy (aged 2 years and older), cervical dystonia (involuntary neck muscle contraction), blepharospasm (involuntary eyelid closure), hemifacial spasm, severe axillary hyperhidrosis (excessive underarm sweating), and urinary incontinence due to neurogenic detrusor overactivity in patients with spinal cord injury or multiple sclerosis.
The onset of Dysport's effect typically occurs within 2 to 3 days after injection. The peak therapeutic effect develops over approximately 2 to 4 weeks. The duration of action is generally 12 to 16 weeks, depending on the condition being treated and individual patient factors. Treatment can be repeated when the clinical benefit begins to wear off, at intervals determined by your doctor.
No. Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA) are both botulinum toxin type A products but they are different formulations with distinct potency unit systems. The units used for Dysport cannot be directly converted to or compared with Botox units. The two products differ in their molecular composition, diffusion characteristics, and approved dosing. Your doctor will choose the most appropriate product for your condition.
In rare cases, the effects of botulinum toxin can spread beyond the injection site to affect muscles involved in swallowing and breathing. This is more likely at higher doses or in patients with pre-existing neuromuscular conditions. Swallowing difficulty (dysphagia) is a known and relatively common side effect when treating cervical dystonia. If you experience any difficulty breathing, swallowing, or speaking after a Dysport injection, contact your doctor or seek emergency medical care immediately.
Dysport must only be administered by a trained physician with specific expertise in botulinum toxin therapy. The powder is first reconstituted with sterile preservative-free saline solution. Depending on the condition, it is injected into the affected muscles (intramuscularly), into the skin (intradermally for hyperhidrosis), under the skin (subcutaneously for blepharospasm), or into the bladder wall via cystoscopy (for neurogenic urinary incontinence). The syringe is for single-patient, single-use only.
Yes, Dysport is approved for the treatment of limb spasticity in children aged 2 years and older with cerebral palsy. It is used to treat both lower limb spasticity (equinus foot deformity affecting walking) and upper limb spasticity. Dosing in children is weight-based and carefully calculated by the treating physician. Dysport is not approved for use in children under 2 years of age.
References
- European Medicines Agency (EMA). Dysport – Summary of Product Characteristics. Updated 2026. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Dysport – Prescribing Information. Ipsen Biopharmaceuticals, Inc. Available at: fda.gov
- Simpson DM, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1818–1826. doi:10.1212/WNL.0000000000002560
- Wissel J, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25. doi:10.2340/16501977-0303
- Naumann M, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Neurology. 2008;70(19):1707–1714. doi:10.1212/01.wnl.0000311390.87642.d8
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Geneva: World Health Organization.
- Herd CP, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616. doi:10.1002/14651858.CD011616.pub2
- Dressler D, et al. Botulinum toxin therapy: past, present and future developments. J Neural Transm. 2023;130(5):721–732. doi:10.1007/s00702-023-02592-4
- British National Formulary (BNF). Botulinum toxin type A – Dysport. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Ipsen Ltd. Dysport 300 units – Patient Information Leaflet. Last revised January 2026.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians with expertise in neurology, rehabilitation medicine, and clinical pharmacology.
Written by specialist physicians with clinical experience in neuromuscular conditions and botulinum toxin therapy.
Reviewed by the iMedic Medical Review Board according to international guidelines (EMA, FDA, AAN). All claims verified against peer-reviewed evidence (Level 1A).
This content follows the iMedic editorial policy: evidence-based, independently written, free from pharmaceutical industry influence. All information is based on the current Summary of Product Characteristics and international clinical guidelines. For full details, see our Editorial Standards.